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Hypertension is a risk factor for cardiovascular disease (CVD), the
leading cause of death in the United States. The treatment and con-
trol  of  hypertension  is  inadequate,  especially  among  patients
without  health  insurance  coverage.  The  Affordable  Care  Act
offered an opportunity to improve hypertension management by
increasing the number of people covered by insurance. This study
predicts the long-term effects of improved hypertension treatment
rates due to insurance expansions on the prevalence and mortality
rates of CVD of nonelderly Americans with hypertension.
Methods
We developed a state-transition model to simulate the lifetime
health events of the population aged 25 to 64 years. We modeled
the effects of insurance coverage expansions on the basis of pub-
lished findings on the relationship between insurance coverage,
use of antihypertensive medications, and CVD-related events and
deaths.
Results
The model projected that currently anticipated health insurance ex-
pansions would lead to a 5.1% increase in treatment rate among
hypertensive patients. Such an increase in treatment rate is estim-
ated to lead to 111,000 fewer new coronary heart disease events,
63,000 fewer stroke events, and 95,000 fewer CVD-related deaths
by 2050. The estimated benefits were slightly greater for men than
for women and were greater among nonwhite populations.
Conclusion
Federal  and state efforts  to expand insurance coverage among
nonelderly adults could yield significant health benefits in terms of
CVD prevalence and mortality rates and narrow the racial/ethnic
disparities in health outcomes for patients with hypertension.
Introduction
In the United States, approximately 78 million people — or 1 in 3
adults — have hypertension, defined as systolic blood pressure of
140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or
higher (1). Hypertension is a risk factor for cardiovascular disease
(CVD), contributing to 35% of myocardial infarctions (MIs) and
strokes, and 49% of heart failures (2). It is estimated that a 5 mm
Hg reduction of systolic blood pressure in the population would
lead to a 9% to 14% reduction in CVD-related mortality rates (3).
Thus, prevention of elevated blood pressure can avert many CVD-
related deaths.
Despite the low cost of antihypertensive medications, there is in-
adequate management of blood pressure at the population level.
National surveys conducted during 2011–2012 show that  only
72% of people with hypertension were taking antihypertensive
drugs, and 53% of hypertensive patients had their blood pressure
under control (4). Lack of insurance coverage is a critical barrier
to better treatment of hypertension. Compared with insured people
with hypertension, uninsured people with hypertension are 4.4
times more likely to have an unmet need for medical care and pre-
scription drugs (5) and have lower treatment and control rates (6).
Health  insurance  expansions  under  the  Affordable  Care  Act
(ACA) offered an opportunity to improve hypertension manage-
ment by increasing the number of people receiving clinical pre-
ventive services (such as routine blood pressure checks) without
cost sharing and by lowering patients’ out-of-pocket costs of anti-
hypertensive medications. The Congressional Budget Office es-
timated that by 2024, Medicaid expansions and federal subsidies
to buy insurance in the Health Insurance Marketplaces would help
25 million uninsured people get insurance coverage (7). However,
little research has been done to understand the extent to which
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such expansion in coverage is likely to improve the health status
of hypertensive patients in the long term. We aimed to project the
long-term effects of health insurance expansions on hypertension
treatment,  CVD incidence rates,  and disease-related mortality
rates, using a state-transition (Markov process) model that simu-
lates the lifetime health events among cohorts of the nonelderly
hypertensive population.
Methods
On the basis of empirical evidence that people with health insur-
ance are more likely to receive antihypertensive medications and
other medical interventions than those who are uninsured (8), we
hypothesized that health insurance expansions would lead to few-
er CVD events and related deaths among the hypertensive popula-
tion. The goal of our model was to estimate changes in the incid-
ence of stroke, coronary heart disease (CHD) —  including MI and
angina pectoris — and disease-caused mortality rates for a cohort
of nonelderly adults, given the expected changes in health insur-
ance rates and first-dollar coverage of preventive services among
adults  following implementation  of  the  ACA.  The  simulation
model ran separately for 8 discrete cohorts stratified by sex and
age (in 10-year increments from 25 to 64). Previous research has
used comparable approaches to project expected effects on CVD
outcomes from changes in blood pressure or cholesterol levels as a
result  of prevention and treatment (9–11).  However,  given the
well-established evidence that antihypertensive medications are
highly effective in preventing CVD, we explicitly modeled health
effects through improvement in the medication rate in the popula-
tion.
Our simulation model estimated how changes in one input (ie,
health insurance rate) lead to changes in other outputs (eg, incid-
ence of CVD events) while isolating the effects of other confound-
ing factors. Findings from this study can contribute to the under-
standing about the long-term impact of access to health insurance
on the hypertensive population. The model also helps to assess
changes in population health outcomes over time, complementing
existing evidence from short-term retrospective data.
Model design
Beginning with simulated year 2014 and at the start of each itera-
tion (a calendar year), the model separates individuals in each co-
hort into 4 separate states: history of MI, history of angina, his-
tory of stroke, or “well” (ie, hypertension with no CVD history).
In each simulated year, every individual may develop a CHD or
stroke event, stay CVD-free, or die of a non-CVD cause; the prob-
abilities of these events vary depending on whether an individual
receives antihypertensive medications. Furthermore, each CVD
event is associated with a certain probability of death, depending
on the disease type and the patient’s age, insurance status, and dis-
ease history. Insurance status was randomly assigned at the begin-
ning of each year, and the probability of insurance varied accord-
ing to 3 policy scenarios.
Figure 1 shows the state transitions for one piece of the model,
where individuals start the year with a history of MI. At the end of
each iteration,  the model removes simulated deaths from each
age–sex cohort, and the remaining lives carry on to the next simu-
lated year. The lives that carry over also retain the history of cardi-
ovascular  outcomes  acquired  in  the  year  that  just  completed,
which changes the risk profile of the cohort (ie, the distribution of
the 4 CVD risk groups) for the following year. This iterative pro-
cess  continues  for  the  equivalent  of  37  simulated  years
(2014–2050). Following the conclusion of the iterative model runs
of each age–sex cohort, we computed the accumulated number of
new CVD events and deaths until 2050. Finally, we computed the
population-level CVD incidence and deaths by aggregating out-
comes of all cohorts according to the age–sex distribution of hy-
pertension prevalence (4).
Figure  1.  Simplified  diagram of  the  Markov  process.  Abbreviation:  CHD,
coronary  heart  disease;  CVD,  cardiovascular  disease;  MI,  myocardial
infarction.
 
Policy scenarios and data input measures
We compared the population-level incidence of CVD and deaths
by 2050 under 3 policy scenarios:
PREVENTING CHRONIC DISEASE VOLUME 12, E105
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY           JULY 2015
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
2       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2015/15_0111.htm
The baseline scenario simulated the absence of reforms in-
cluded in the ACA, with percentages insured and uninsured re-
maining roughly the same as they were before enactment (12).
1.
The first expansion scenario simulated an expansion based on
current expectations (as of January 2014) for insurance expan-
sions under the ACA and assumed that all undecided states
will opt out of expanding Medicaid throughout 2050. Insur-
ance coverage levels were based on research results reported
by Nardin et al (13), which estimated that 13.9 million previ-
ously uninsured nonelderly adults would gain health insurance
coverage under the ACA. These estimates were consistent with
the observed decrease in the number of uninsured adults
between 2013 and 2015 (14).
2.
The second expansion scenario simulated an expansion that
achieves 100% insurance for all age groups. This scenario goes
beyond full implementation of the ACA, estimating the upper
bounds on insurance-related effects that help to put the results
from other scenarios into context.
3.
The average annual incidence of CHD and stroke, by age and sex,
was computed using β coefficients from Framingham CVD risk
functions (15). The predictions of these functions have been valid-
ated with data from other ethnically diverse studies (16) and have
been  widely  used  in  simulation  models  of  CVD  prevention
strategies (10,17). Risk factors for CHD and stroke were derived
from  National  Health  and  Nutrition  Examination  Survey
2011–2012  data,  including  sex,  age,  systolic  blood  pressure,
smoking status, level of total serum cholesterol,  level of high-
density lipoprotein cholesterol, and the presence of diabetes. The
distribution  of  CHD  events  (MI,  stable  angina,  and  unstable
angina) was obtained from the Healthcare Cost and Utilization
Project hospital inpatient data (18).
The likelihood of receiving antihypertensive medications by insur-
ance status was based on estimates reported by Brooks et al (19)
The age-specific effects of antihypertensive medications on CHD
and stroke and 1-year mortality rates after CVD events were col-
lected from published medical literature (12,13,20–30). (For com-
plete information on input parameters, see the Appendix.)
We estimated the effects of health insurance expansions by race/
ethnicity using the same process. Framingham CVD risk func-
tions were used to estimate the probabilities of CVD events separ-
ately for each age-racial/ethnic group. For these scenarios, estim-
ates of pre-ACA and post-ACA insurance rates by race/ethnicity
were based on estimates reported by Clemans-Cope et al (31).
Sensitivity analysis
We used Monte Carlo simulations to account for uncertainties
about the disease transition probabilities at the individual level that
could affect future outcomes. The probability of each CVD event
was defined as a normally distributed random variable with means
and standard deviations estimated from the Framingham CVD risk
functions. The standard errors of disease prevalence and mortality
rates were obtained from results of 1,000 simulations.
Past research found that longer periods without insurance are asso-
ciated with access problems; thus, greater health benefits are likely
to accrue for individuals with continuous coverage throughout
their lifetimes (32). To test the effects of continuous coverage, we
estimated an alternative model in which individuals in the same
sex-age-insurance cohort remain either insured or uninsured for
the duration of the simulation (Appendix). Additional analyses in-
vestigated the effects of including people with prehypertension
(defined as systolic blood pressure of 120–139 mm Hg or diastol-
ic blood pressure of 80–89 mm Hg). All analyses were performed
using Treeage Pro 2013 (Treeage Software, Williamstown, Mas-
sachusetts).
Results
Under the first expansion scenario, where all states currently unde-
cided about Medicaid expansion opt out, the proportion of the cur-
rent cohort of hypertensive patients being treated with antihyper-
tensive medications is estimated to increase from 56.7% to 59.5%
(Table 1). Younger adults would experience proportionally great-
er increase in treatment rates: rates for people aged 25 to 34 would
increase by 9.4%, and rates for people aged 55 to 64 would in-
crease by 3.4%. The changes in projected treatment rates were lar-
ger for men than for women, primarily because the current treat-
ment rates for men are significantly below those for women. If all
adults aged 25 to 64 obtained insurance coverage, the hyperten-
sion treatment rate would rise to 63.5%.
The model predicted that if currently undecided states opt out of
the Medicaid expansion and hypertension treatment rates remain
constant, by 2050, the number of new cases of CHD would be re-
duced by 111,000 (0.55%) and the number of new cases of stroke
by 63,000 (0.75%); the number of CVD-related deaths would de-
cline  by  95,000  (1.16%)  (Table  2).  If  all  currently  uninsured
people get insurance coverage, the incidence of CHD and stroke
would decline by 1.48% and 1.3% respectively, and CVD-related
mortality would decline by 2.73%. Both sexes were expected to
benefit from the insurance expansions; the estimated benefits are
greater for men than for women. Although the absolute numbers
of new cases and deaths averted were estimated to be greater for
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the white population, the relative improvement in outcomes was
expected to be greater for nonwhite Hispanics (Table 3). Relative
to the baseline scenario, Hispanics were expected to have 2.07%
fewer CHD cases and 1.06% fewer stroke cases under the first ex-
pansion scenario, compared with the 0.51% and 0.5% reductions
for whites. The health effects of averted CVD events therefore
translate into a greater mortality rate reduction for Hispanics than
whites (3.84% vs 1.19%).
All age groups were expected to have reduced incidence of CVD
events and lower mortality rates from CVD following the insur-
ance expansions (Figure 2). The estimated reductions in mortality
were largest for adults aged 25 to 34: by 1.2% to 3.2% if currently
undecided states opt out of Medicaid expansions, and by 2.4% to
9.4% if all adults eventually have insurance coverage. Again, the
estimated benefits are greater for nonwhite populations in each age
group.
Figure 2. Estimated reduction in cardiovascular events and mortality rates
under  insurance  expansions  for  white,  black,  and  nonwhite  Hispanic
populations, by age group. These charts illustrate the racial/ethnic-specific
effects  of  insurance  coverage  expansion  by  age  group.  Outcomes  are
measured by percentage reduction in cardiovascular events and mortality
rates. Scenario 1 assumes currently undecided states opting out of Medicaid
expansion, and scenario 2 assumes the entire US population is covered by
insurance.
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As expected, the model predicted greater health effects when indi-
viduals were assumed to maintain their insurance status over time
(Appendix). In the first expansion scenario, improved medication
rates would prevent 307,000 CHD cases (1.42%), 138,000 stroke
cases (1.18%), and 217,000 CVD-related deaths (2.61%). In the
second  scenario,  there  would  be  485,000  fewer  CHD  cases
(2.24%), 266,000 fewer stroke cases (2.26%), and 513,000 fewer
CVD-related deaths (6.15%).
When including all adults with prehypertension, the estimated rel-
ative effects of expansion remain similar to the baseline results
(Appendix). Nevertheless, the predicted population-wide benefits
in terms of the CVD cases averted and lives saved are greater, be-
cause an additional 53 million adults with prehypertension would
benefit from early interventions due to coverage expansions. Spe-
cifically, the model projects that insurance expansions would re-
duce CHD cases by 253,000 to 535,000; stroke cases by 77,000 to
189,000; and deaths by 165,000 to 364,000.
Discussion
One objective of the ACA is to improve disease prevention by ex-
panding health insurance coverage and access to preventive care.
Findings from this study indicate the potential public health bene-
fits from such efforts. It is estimated that improved hypertension
treatment  rates  due  to  insurance  expansions  would  prevent
174,000 to 408,000 new CHD and stroke cases by 2050, a 0.61%
to 1.43% decline from the baseline. Heidenreich et al (33) estim-
ated that CHD and stroke cost $197.3 billion (2008 dollars) in
2015, including direct medical costs and indirect costs from ill-
ness and premature death. Applying these estimates to our results
yields a cost savings of $1.2 to $2.8 billion per year. We also pro-
jected that increased hypertension treatment rates due to expan-
sion would prevent 95,000 to 222,000 CVD-related deaths among
the current cohort of nonelderly hypertensive patients, represent-
ing 2,568 to 6,000 lives saved annually.
These results build on findings from the lottery-based Medicaid
expansion in Oregon, which indicated that previously uninsured
low-income adults who were randomly selected into Medicaid re-
ported increased use of medication for hypertension, hypercholes-
terolemia, and diabetes, and better self-reported physical and men-
tal health, than low-income adults who remained uninsured (34).
Nevertheless, significant improvement in clinical outcomes, such
as blood pressure, cholesterol level, and glucose level, was not ob-
served in the first 2 years following the expansion. As the authors
acknowledged, the short study period may be a limiting factor, be-
cause the health benefits of having insurance may not be realized
immediately.  Thus,  our  results  indicate that  when considering
whether to implement health insurance expansions, states should
consider  the  population  health  benefits  and  cost-savings  that
would be realized in the long term.
Our estimate of a 1.2% to 2.7% reduction in population mortality
is smaller than the estimate by Sommers et al of 6% (35). There
are several explanations for this difference. Besides coverage for
antihypertensive drugs, health insurance provides patients with
timely outpatient care, chronic disease management, and laborat-
ory services, all of which are likely to generate health benefits that
are not  captured in our model.  Our estimates also exclude the
health effects of insurance expansion on other conditions such as
diabetes and mental illness. Given that the insurance coverage pro-
vision under the ACA is expected to cost $76 to $145 billion an-
nually for the next decade (7), more research is needed to compre-
hensively evaluate the health and economic effects of this health
system reform.
Our study has limitations. Our model predicted greater benefits for
certain subpopulations. Men would receive greater benefits than
women (eg, 1.23% decrease in mortality for men vs 1.07% for wo-
men in the first expansion scenario), because men have a higher
lifetime risk of CVD (36). Young and middle-aged adults (25 to
54 y) would experience proportionally greater reductions in mor-
tality rates, largely because early treatment of hypertension effect-
ively prevents or delays the onset of CVD.
Our findings also suggest that the ACA’s insurance expansions
would narrow the racial/ethnic disparities in health outcomes, a
finding consistent with recent studies (35,37). In particular, non-
white Hispanics would proportionally benefit the most from the
coverage expansions because they have the lowest pre-ACA insur-
ance rate among all racial/ethnic groups (31). Blacks would also
receive proportionally larger benefits than whites, because they
have the highest rates of hypertension as well as other CVD risk
factors, such as diabetes and obesity (38).
There are several limitations of this analysis. As with almost all
policy assessment tools, the size of our estimates depends on a
range of assumptions about the population in future decades. As
discussed previously, our analysis focuses on the impact of im-
proved medication rates and does not fully consider other poten-
tial benefits from insurance expansions. Our main analysis also
does not account for possible effects of health insurance expan-
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sions  on  preventing  the  onset  of  hypertension  among healthy
adults and adolescents — for example, potential reduction in hy-
pertension prevalence because of lifestyle interventions and health
education. As shown in the sensitivity analysis, insurance expan-
sions also have positive effects on people with prehypertension.
Conversely, factors that delay enrollment of uninsured individuals
in Medicaid, insurance exchanges, or both, or that limit their abil-
ity to access care once insured, may lower the estimated effects.
Second, the estimates of baseline disease risks stratified by age,
sex, and race/ethnicity are extrapolated from clinical-trial data col-
lected in the 1980s, so any uncertainty about the effects of CVD
risk factors on the current population would limit the accuracy of
projections. Nevertheless, results from the fitted Framingham risk
functions suggest that estimates of CVD risks are accurate, and
Monte Carlo simulations show that small variations in baseline
CVD risks have little impact on the estimated numbers of CVD
events and deaths. However, the model did not account for year-
to-year changes of CVD risks in the 10-year increments among
cohorts or for future medical advances that may improve hyperten-
sion treatment efficacy. We were also unable to differentiate the
burden of CVD disease in expansion and nonexpansion states.
Finally, another uncertainty concerns how health care reform af-
fects the stability of individuals’  insurance coverage.  Existing
modeling  approaches  (eg,  the  Coronary  Heart  Disease  Policy
Model [11]) typically estimate the effect of a population-wide,
constant reduction in health risk factors, such as sodium intake, on
health outcomes. Unlike these models, we did not make explicit
assumptions about individuals’ insurance status throughout their
lifetimes. Instead, our estimation was driven by the mix of insured
and uninsured among the current cohort of individuals aged 25 to
64, over future decades. Although our sensitivity analysis showed
greater health effects when people have continuous insurance cov-
erage, in practice, little is known about how often individuals drop
insurance coverage and whether insurance reforms will shorten the
average coverage gap. More research is needed to address these
uncertainties.
Even  with  these  limitations,  this  study  demonstrates  that  im-
proved hypertension treatment through the expansion of health in-
surance coverage would yield substantial health benefits for the 55
million nonelderly hypertensive adults in the United States. Fu-
ture research should include additional analyses of the effects of
comprehensive insurance benefit packages and improved blood
pressure monitoring in home and ambulatory settings.
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Tables
Table 1. Estimated Effects of Health Insurance Expansion on Hypertension Treatment Rates by 2016
Scenario/
Sex
Nonelderly Adults With Hypertension, % Receiving Treatment (% Change Under Expansion)
All adults (N =
54,697,510)
Aged 25–34 (n =
3,911,740)
Aged 35–44 (n =
10,190,086)
Aged 45–54 (n =
17,326,094)
Aged 55–64 (n =
23,269,590)
Baseline scenario: no expansion
US total 56.7 ( — ) 51.5 ( — ) 53.3 ( — ) 57.0 ( — ) 58.8 ( — )
Male 50.8 ( — ) 45.9 ( — ) 47.2 ( — ) 51.6 ( — ) 53.0 ( — )
Female 62.5 ( — ) 58.8 ( — ) 59.8 ( — ) 62.8 ( — ) 63.8 ( — )
Scenario 1: currently undecided states opting out of Medicaid expansion
US total 59.5 (5.1) 56.3 (9.4) 56.9 (6.8) 60.2 (5.6) 60.7 (3.4)
Male 54.3 (6.8) 51.4 (12.1) 51.4 (8.9) 55.4 (7.2) 55.4 (4.5)
Female 64.8 (3.7) 62.7 (6.6) 62.7 (4.9) 65.4 (4.2) 65.4 (2.6)
Scenario 2: all US population under insurance coverage
US total 63.5 (12.1) 62.9 (22.2) 63.3 (18.9) 63.4 (11.1) 63.8 (8.6)
Male 59.0 (16.1) 59.0 (28.6) 59.0 (25.0) 59.0 (14.3) 59.0 (11.4)
Female 68.0 (8.8) 68.0 (15.6) 68.0 (13.8) 68.0 (8.2) 68.0 (6.6)
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Table 2. Estimated Effects of Health Insurance Expansion on Nonelderly Adults With Hypertension, by Sex
Scenario/Sex
No. of CVD Events and CVD-Related Deaths Per 10,000 Populationa
CHD Stroke CVD Death
Baseline scenario: no expansion, no. (95% CI)
Total 2,022 (1,914–2,130) 837 (769–905) 816 (763–869)
Male 1,366 (1,303–1,429) 424 (391–457) 474 (446–502)
Female 648 (603–693) 421 (386–456) 342 (317–367)
Scenario 1: currently undecided states opting out of Medicaid expansion
Total, no. (95% CI) 2,011 (1,906–2,116) 831 (763–899) 806 (753–859)
Difference (% change) 11.1 (−0.55) 6.3 (−0.75) 9.5 (−1.16)
Male, no. (95% CI) 1,358 (1,297–1,419) 420 (385–455) 468 (440–496)
Difference (% change) 8.3 (−0.61) 4.1 (−0.96) 5.8 (−1.23)
Female, no. (95% CI) 645 (596–694) 419 (379–459) 338 (303–373)
Difference (% change) 2.8 (−0.43) 2.3 (−0.54) 3.7 (−1.07)
Scenario 2: all US population under insurance coverage
Total, no. (95% CI) 1,992 (1,884–2,100) 826 (761–891) 794 (744–844)
Difference (% change) 29.9 (−1.48) 10.9 (−1.30) 22.2 (−2.73)
Male, no. (95% CI) 1,344 (1,281–1,407) 418 (386–450) 460 (434–486)
Difference (% change) 21.9 (−1.6) 6.3 (−1.49) 14.0 (−2.96)
Female, no. (95% CI) 640 (590–690) 416 (377–455) 334 (299–369)
Difference (% change) 7.9 (−1.21) 4.8 (−1.14) 8.2 (−2.41)
Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease.
a Values expressed as no. (95% CI), unless otherwise indicated. 95% CIs obtained from Monte Carlo simulations.
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Table 3. Estimated Effects of Health Insurance Expansion on Nonelderly Adults with Hypertension, By Race/Ethnicitya,b
Scenario and Race/Ethnicity
CVD Events and CVD-Related Deaths Per 10,000 population
CHD Stroke CVD death
Baseline scenario: no expansion, no. (95% CI)
White 1,310 (1,237–1,383) 534 (488–580) 528 (491–565)
Black 340 (321–359) 175 (162–188) 152 (143–161)
Nonwhite Hispanic 22.8 (21.6–24.0) 7.6 (6.9–8.3) 5.0 (4.5–5.5)
Scenario 1: currently undecided states opting out of Medicaid expansion
White, no. (95% CI) 1,304 (1,231–1,377) 531 (485–577) 522 (487–557)
Difference (% change) 6.7 (−0.51) 2.7 (−0.5) 6.3 (−1.19)
Black, no. (95% CI) 336 (318–354) 173 (160–186) 148 (139–157)
Difference (% change) 3.5 (−1.04) 1.9 (−1.1) 3.2 (−2.14)
Nonwhite Hispanic, no. (95% CI) 22.4 (21.1–23.6) 7.5 (6.8–8.2) 4.8 (4.4–5.2)
Difference (% change) 0.5 (−2.07) 0.1 (−1.06) 0.2 (−3.84)
Scenario 2: all US population under insurance coverage
White, no. (95% CI) 1,295 (1,223–1,367) 529 (484–574) 517 (482–552)
Difference (% change) 15.4 (−1.17) 4.6 (−0.87) 11.3 (−2.15)
Black, no. (95% CI) 332 (314–350) 172 (159–185) 146 (137–155)
Difference (% change) 7.2 (−2.12) 3.5 (−1.97) 6.1 (−4)
Nonwhite Hispanic, no. (95% CI) 21.6 (20.5–22.7) 7.4 (6.7–8.1) 4.5 (4.1–4.9)
Difference (% change) 1.3 (−5.63) 0.2 (−2.57) 0.5 (−9.79)
Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease.
a Values expressed as no. (95% CI), unless otherwise indicated. 95% CIs obtained from Monte Carlo simulations.
b Pre- and post-ACA insurance rates for race/ethnicity groups were adjusted according to the age distribution of insurance status reported by The Kais-
er Commission on Medicaid and the Uninsured (12).
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Appendix.
Estimation of Model Input Parameters and Results of Sensitivity Analysis. This file is available for download as a Microsoft
Word document [DOCX – 32.8 KB].
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